Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 21, 2010

View Archived Issues

Ramucirumab is tolerated in patients with advanced HCC in ongoing phase II trial

Almirall identifies new naphthyridine N-oxide as anti-inflammatory agent

Scientists reveal predictors of adverse events associated with losartan therapy for heart failure

Novel ACAT-1 inhibitors presented by Galderma

Scientists create Maraba MG1 virus strain with increased tumor-selective potency

NFL-10808 silences presynaptic serotonin 5-HT1A receptors and has antidepressant effects in vivo

Daiichi Sankyo identifies new inhibitors of HSP 90 ATPase activity

Ligand Pharmaceuticals and Proximagen collaborate on chemokine CXCR4 receptor target

Trial of TT-223/GLP-1 analogue combination in type 2 diabetes does not meet endpoints

RaQualia Pharma claims new motilin receptor agonists

Vantia identifies new vasopressin V1A receptor antagonists

LigoCyte begins phase I trial of bivalent intramuscular norovirus vaccine

Novel COX-1 inhibitors described by Japanese scientists

ImmunoCellular Therapeutics begins phase II glioblastoma study of ICT-107

Ablynx reports follow-up data from phase I study of ALX-0141

Faron Pharma advances FP-1201 into second part of trial in acute lung injury

Novartis Europharm withdraws Rasival MAA for essential hypertension

Phase III Northera trial meets endpoint in neurogenic orthostatic hypotension

Icagen suspends enrollment in photosensitivity study of ICA-105665

Boehringer Ingelheim begins phase III afatinib trial in breast cancer

EMA updates nevirapine label for patients with HIV-1 infection

Synvisc is approved in Japan for osteoarthritis of the knee

Hybrigenics reports phase IIa data on inecalcitol/docetaxel combination in prostate cancer

Endo Pharma completes tender offer for Penwest Pharma shares

SCH-527123 is safe and efficacious in phase II trial in COPD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...